Long since shelving an attempt to go public, antibiotics developer Paratek Pharmaceuticals has signed a deal that will give it a Wall Street debut after all, planning a reverse merger with the struggling Transcept Pharmaceuticals and picking up a $93 million investment along the way.

…read more

Source: Paratek absorbs the troubled Transcept in a reverse merger


0 No comments